CA2035443C - Analgesic and inflammation-inhibiting medicament - Google Patents
Analgesic and inflammation-inhibiting medicament Download PDFInfo
- Publication number
- CA2035443C CA2035443C CA002035443A CA2035443A CA2035443C CA 2035443 C CA2035443 C CA 2035443C CA 002035443 A CA002035443 A CA 002035443A CA 2035443 A CA2035443 A CA 2035443A CA 2035443 C CA2035443 C CA 2035443C
- Authority
- CA
- Canada
- Prior art keywords
- medicament
- vol
- inflammation
- analgesic
- populus tremula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/76—Salicaceae (Willow family), e.g. poplar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The use is described of the medicament with analgesic and inflammation- suppressing action based on plants and containing populus tremula, solidago virgaurea and fraxinus excelsior as the sole active vehicle as a basic therapeutic.
Description
(,~ :i !i ;i Analgesic and inflammation-inhibiting medicament The use of the medicament having analgesic and inflammation-inhibiting action on a plant basis and containing the constituents Populus tremula Solidago virgaurea Fraxinus excelsior as the sole carrier of the activity as a basic therapeu-tic is described.
~ v a x .._ - 2 -Analgesic and inflammation-inhibiting medicament The invention relates to an analgesic and inflammation-inhibiting medicament.
In the therapy of inflammatory rheumatological diseases, in particular rheumatoid arthritis, two different medicinal principles are used side by side. The first consists in the reduction of the pain and the inflammatory symptoms in the joint concerned. Various classes of substance, for example salicylic acid ~leriva-Lives, acetic and propionic acid derivatives or oxicams are used for this purpose. A summarising expression is "non-steroidal antirheumatics" (NSAR). Their activity is evaluated in the joint concerned itself. The effects occur rapidly (hours to days). The dose is suited to the immediate situation. A change in course of the. inflam~
matory rheumatic disease does not occur as a result of these medicaments.
The medicament purely on a plant basis described in the WTPO document (T~TO, 87/02248) likewise has the effects of the non-steroidal antirheumatics (NEAP,) together with better tolerability.
In addition to the activity described, agents are known and are intensively additionally sought, which favourably influence the entire course of incurable chronic diseases (so-called disease-modifying drugs).
They influence pain and inflammation only after long administration ( over a period of months ) ~,aith maintenance doses and are afflicted with considerable side effects-(about a third of the patients have to discontinue this treatment). Their activity is initially recognised in an improdement in the signs of systemic inflammation. This is in particular an improvement in the erythrocyte sedimentation test, which is generally used as a method for the assessment of an inflammatory event. Other tests, _ - ~ » ~l ~l Cl i !~
which, in principle, give no other evidence, are, for example, C-reactive protein (CPR). The long-term ai.m in this treatment is the reduction or avoidance of joint destruction by rheumatic inflammation. This therapy is familiar today under the name basic therapy.
Because of frequent and occasionally critical side effects, there are carefully worked out rules for treatment with basic therapeutics. For example, results from a 20-week double blind study should be quoted for the change in the erythrocyte sedimentation test (Ward, J.R. et al., Arthritis and Rheumatism Vol. 26, No. 11, 1983, pages 1303 - 1315).
Medicament ESR before ESR after 20 therapy weeks Placebo 55 51 Auranofin 63 22 Gold Na thioma- 58 33 late ESR =
Erythrocyte sedimentation rate in min/h only for the first hour Surprisingly, it has now been found in an inves-tigation in various research centres that basic therapeutic effects were also achieved using the medics--went disclosed in WO
87/02248.
This medicament having analgesic and inflammation-inhibiting action on a.
plant basis is distinguished by the constituents Populus tremula, Solidago virgaurea and Fraxinus excelsior as the sole carriers of the activity.
Tt has proved advantageous if the medicament "..
according to the invention contains vol.-~
of Populus tremula, vol.-~
of Solidago virgaurea and vol.--~
of Fraxinus excelsior.
A particularly preferred composition of the medicament according to. the invention contains about v .' J ~' 1 . "7 - 4 - ~d~~~;'x~
60 vol.-~ of Populus tremula, 20 vol.-~ of Solidago virgaurea and 20 vol.-~ of Fraxinus excelsior.
It is finally in the scope of the invention that bark and leaves are present in the ratio 1 . 2 in the constituent Populus tremula.
The present invention consists in the surprising discovery that this medicament can be employed not only for the immediate treatment of rheumatic diseases, but rather, in particular, also as a basic therapeutic.
As an example of the basic therapeutic action of the medicament identified according to the invention, results of investigations in the rheumatological depart-ment of a hospital are reproduced, in particular by means of the CRP values of the medicament according to WO 87/02248. A clear reduction in these values is shown.
It can be safely said that owing to the administration of the medicament of WO 87/02248, the inflammatory activity of the rheumatological diseases - expressed by C-reactive protein - was clearly lowered. Some results are given below in tabular form:
CRP Values Time interval Average value Standard deviation Before WO 87/02248 i 46.2 32.1 After 3 months 37.4 30.9 After 6 months 32.9 26.4 After 9 months ~ 29.4 21.8 After 12 months 27 . 9 21 > 3 r ~ ~
Care has to be taken i,n this case that the patients in both groups investigated here have addi-- tionally received a long-term basic therapy which has already beers, carried out for a long time at the beginning of the test. This was not changed, as the discovery was unforeseeable. The effects as a result of the medicament on a plant basis according to WO 87/02248 consequently go beyond effects already achieved. 7Cn this case; the group of the medicaments on a plant basis according t~
~, .~ ~ r) WO 87/02248 starts out from more unfavourable values than the placebo group.
Under these conditions, a reduction in the erythrocyte sedimentation test of 31 ~ is a considerable effect.
During monitoring of 5 patients with rheumatoid arthritis who had already been treated, it turned out that as a result of additional administration of the medicament on a plant basis according to WO 87/02248, downward changes, i.e, in the therapeutic direction, occur (lacuna) the starting values in three out of five cases in the erythrocyte sedimentation test and in four out of five cases- with C-reactive protein within four weeks. This clear effect is surprising for several reasons:
1. The dosages used here have not been determined with respect to the basic therapeutic activity.
They correspond, rather, to the dose on symptoma~.
tic therapy.
~ v a x .._ - 2 -Analgesic and inflammation-inhibiting medicament The invention relates to an analgesic and inflammation-inhibiting medicament.
In the therapy of inflammatory rheumatological diseases, in particular rheumatoid arthritis, two different medicinal principles are used side by side. The first consists in the reduction of the pain and the inflammatory symptoms in the joint concerned. Various classes of substance, for example salicylic acid ~leriva-Lives, acetic and propionic acid derivatives or oxicams are used for this purpose. A summarising expression is "non-steroidal antirheumatics" (NSAR). Their activity is evaluated in the joint concerned itself. The effects occur rapidly (hours to days). The dose is suited to the immediate situation. A change in course of the. inflam~
matory rheumatic disease does not occur as a result of these medicaments.
The medicament purely on a plant basis described in the WTPO document (T~TO, 87/02248) likewise has the effects of the non-steroidal antirheumatics (NEAP,) together with better tolerability.
In addition to the activity described, agents are known and are intensively additionally sought, which favourably influence the entire course of incurable chronic diseases (so-called disease-modifying drugs).
They influence pain and inflammation only after long administration ( over a period of months ) ~,aith maintenance doses and are afflicted with considerable side effects-(about a third of the patients have to discontinue this treatment). Their activity is initially recognised in an improdement in the signs of systemic inflammation. This is in particular an improvement in the erythrocyte sedimentation test, which is generally used as a method for the assessment of an inflammatory event. Other tests, _ - ~ » ~l ~l Cl i !~
which, in principle, give no other evidence, are, for example, C-reactive protein (CPR). The long-term ai.m in this treatment is the reduction or avoidance of joint destruction by rheumatic inflammation. This therapy is familiar today under the name basic therapy.
Because of frequent and occasionally critical side effects, there are carefully worked out rules for treatment with basic therapeutics. For example, results from a 20-week double blind study should be quoted for the change in the erythrocyte sedimentation test (Ward, J.R. et al., Arthritis and Rheumatism Vol. 26, No. 11, 1983, pages 1303 - 1315).
Medicament ESR before ESR after 20 therapy weeks Placebo 55 51 Auranofin 63 22 Gold Na thioma- 58 33 late ESR =
Erythrocyte sedimentation rate in min/h only for the first hour Surprisingly, it has now been found in an inves-tigation in various research centres that basic therapeutic effects were also achieved using the medics--went disclosed in WO
87/02248.
This medicament having analgesic and inflammation-inhibiting action on a.
plant basis is distinguished by the constituents Populus tremula, Solidago virgaurea and Fraxinus excelsior as the sole carriers of the activity.
Tt has proved advantageous if the medicament "..
according to the invention contains vol.-~
of Populus tremula, vol.-~
of Solidago virgaurea and vol.--~
of Fraxinus excelsior.
A particularly preferred composition of the medicament according to. the invention contains about v .' J ~' 1 . "7 - 4 - ~d~~~;'x~
60 vol.-~ of Populus tremula, 20 vol.-~ of Solidago virgaurea and 20 vol.-~ of Fraxinus excelsior.
It is finally in the scope of the invention that bark and leaves are present in the ratio 1 . 2 in the constituent Populus tremula.
The present invention consists in the surprising discovery that this medicament can be employed not only for the immediate treatment of rheumatic diseases, but rather, in particular, also as a basic therapeutic.
As an example of the basic therapeutic action of the medicament identified according to the invention, results of investigations in the rheumatological depart-ment of a hospital are reproduced, in particular by means of the CRP values of the medicament according to WO 87/02248. A clear reduction in these values is shown.
It can be safely said that owing to the administration of the medicament of WO 87/02248, the inflammatory activity of the rheumatological diseases - expressed by C-reactive protein - was clearly lowered. Some results are given below in tabular form:
CRP Values Time interval Average value Standard deviation Before WO 87/02248 i 46.2 32.1 After 3 months 37.4 30.9 After 6 months 32.9 26.4 After 9 months ~ 29.4 21.8 After 12 months 27 . 9 21 > 3 r ~ ~
Care has to be taken i,n this case that the patients in both groups investigated here have addi-- tionally received a long-term basic therapy which has already beers, carried out for a long time at the beginning of the test. This was not changed, as the discovery was unforeseeable. The effects as a result of the medicament on a plant basis according to WO 87/02248 consequently go beyond effects already achieved. 7Cn this case; the group of the medicaments on a plant basis according t~
~, .~ ~ r) WO 87/02248 starts out from more unfavourable values than the placebo group.
Under these conditions, a reduction in the erythrocyte sedimentation test of 31 ~ is a considerable effect.
During monitoring of 5 patients with rheumatoid arthritis who had already been treated, it turned out that as a result of additional administration of the medicament on a plant basis according to WO 87/02248, downward changes, i.e, in the therapeutic direction, occur (lacuna) the starting values in three out of five cases in the erythrocyte sedimentation test and in four out of five cases- with C-reactive protein within four weeks. This clear effect is surprising for several reasons:
1. The dosages used here have not been determined with respect to the basic therapeutic activity.
They correspond, rather, to the dose on symptoma~.
tic therapy.
2. The effects observed are additional effects in the basic therapy already carried out. In the case of the discovery, it would be ethically unjustifiable to withhold a known effective therapy from the seriously ill. It was completely unexpected that a further increase in the basic therapeutic activity could occur over and above this traditional therapy.
3. For the appreciation of the discovery, it has to be considered that the medicament on a plant .
basis according to WO 87/02248 is essentially better tolerated compared to other antirheunaa-.
tics. From this, there is the possibility 3:1 both to achieve greater effects by means of h~.gher doses and .
3.2 to increase their effectiveness further by additional use of the medicamewt according to WC) 87/02248 in addition t~ traditional basic therapy .
basis according to WO 87/02248 is essentially better tolerated compared to other antirheunaa-.
tics. From this, there is the possibility 3:1 both to achieve greater effects by means of h~.gher doses and .
3.2 to increase their effectiveness further by additional use of the medicamewt according to WC) 87/02248 in addition t~ traditional basic therapy .
Claims (4)
1. Use of the medicament having analgesic and inflammation-inhibiting action on a plant basis and containing the constituents Populus tremula Solidago virgaurea Fraxinus excelsior as the sole carrier of the activity as a basic therapeutic.
2. Use of the medicament according to Claim 1, containing about 50 - 70 vol.-% of Populus tremula - 30 vol.-% of Solidago virgaurea 10 - 30 vol.-% of Fraxinus excelsior as a basic therapeutic.
3. Use of the medicament according to Claim 1 or 2, containing about 60 vol.-% of Populus tremula vol.-% of Solidago virgaurea 20 vol.-% of Fraxinus excelsior as a basic therapeutic.
4. Use of the medicament according to one of Claims 1 to 3, in which bark and leaves are present in the ratio 1 : 2 in the constituent Populus tremula, as a basic therapeutic.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP89112639.3 | 1989-07-11 | ||
| EP89112639A EP0407634B1 (en) | 1989-07-11 | 1989-07-11 | Analgetic and antiinflammatory medicine |
| PCT/EP1990/001114 WO1991000735A1 (en) | 1989-07-11 | 1990-07-09 | Analgesic and inflammation-suppressing medicament |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2035443A1 CA2035443A1 (en) | 1991-01-12 |
| CA2035443C true CA2035443C (en) | 2001-04-10 |
Family
ID=8201609
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002035443A Expired - Fee Related CA2035443C (en) | 1989-07-11 | 1990-07-09 | Analgesic and inflammation-inhibiting medicament |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP0407634B1 (en) |
| JP (1) | JP2752250B2 (en) |
| KR (1) | KR0177137B1 (en) |
| AT (1) | ATE91898T1 (en) |
| CA (1) | CA2035443C (en) |
| DE (1) | DE58905060D1 (en) |
| ES (1) | ES2059648T3 (en) |
| HU (1) | HU212264B (en) |
| LT (1) | LT3655B (en) |
| LV (1) | LV10197B (en) |
| RU (1) | RU2069564C1 (en) |
| WO (1) | WO1991000735A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2065286B1 (en) * | 1993-07-20 | 1995-09-16 | Asins Antonio Gomez | NEW ANALGESIC MEDICINE BASED ON EXTRACTS OF WILD PLANTS AND PROCEDURE FOR ITS PREPARATION. |
| FR2790917B1 (en) * | 1999-03-15 | 2001-05-04 | Genevieve Couleard Vannier | DRINK OF AN ASH-BASED HERBAL TEA |
| US9365460B2 (en) | 2006-11-09 | 2016-06-14 | Akzo Nobel N.V. | Pigment dispersion |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3537160A1 (en) | 1985-10-18 | 1987-04-23 | Steigerwald Arzneimittelwerk | Pain-relieving and anti-inflammatory drug based on plants |
-
1989
- 1989-07-11 ES ES89112639T patent/ES2059648T3/en not_active Expired - Lifetime
- 1989-07-11 EP EP89112639A patent/EP0407634B1/en not_active Expired - Lifetime
- 1989-07-11 AT AT89112639T patent/ATE91898T1/en not_active IP Right Cessation
- 1989-07-11 DE DE8989112639T patent/DE58905060D1/en not_active Expired - Fee Related
-
1990
- 1990-07-09 RU SU904895031A patent/RU2069564C1/en not_active IP Right Cessation
- 1990-07-09 WO PCT/EP1990/001114 patent/WO1991000735A1/en active Application Filing
- 1990-07-09 JP JP2510673A patent/JP2752250B2/en not_active Expired - Fee Related
- 1990-07-09 KR KR1019910700255A patent/KR0177137B1/en not_active IP Right Cessation
- 1990-07-09 HU HU906697A patent/HU212264B/en not_active IP Right Cessation
- 1990-07-09 CA CA002035443A patent/CA2035443C/en not_active Expired - Fee Related
-
1993
- 1993-06-30 LV LVP-93-937A patent/LV10197B/en unknown
- 1993-12-03 LT LTIP1520A patent/LT3655B/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| KR920700665A (en) | 1992-08-10 |
| HU212264B (en) | 1996-04-29 |
| KR0177137B1 (en) | 1999-03-20 |
| WO1991000735A1 (en) | 1991-01-24 |
| DE58905060D1 (en) | 1993-09-02 |
| ES2059648T3 (en) | 1994-11-16 |
| ATE91898T1 (en) | 1993-08-15 |
| HU906697D0 (en) | 1991-07-29 |
| LV10197A (en) | 1994-10-20 |
| LT3655B (en) | 1996-01-25 |
| LTIP1520A (en) | 1995-06-26 |
| JPH04501571A (en) | 1992-03-19 |
| RU2069564C1 (en) | 1996-11-27 |
| JP2752250B2 (en) | 1998-05-18 |
| EP0407634B1 (en) | 1993-07-28 |
| CA2035443A1 (en) | 1991-01-12 |
| HUT57057A (en) | 1991-11-28 |
| LV10197B (en) | 1995-04-20 |
| EP0407634A1 (en) | 1991-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Anderson et al. | Effects of treatment with U-74006F on neurological outcome following experimental spinal cord injury | |
| DE68916387T2 (en) | Use of nalmefene or naltrexone in the treatment of autoimmune diseases. | |
| DE69636413T2 (en) | ADMINISTRATIVE MEDIUM FOR ANALGETIC, ANTI-INFLAMMATORY AND ANTIPYRETIC AGENTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH MEDIA AND ACTIVE SUBSTANCES | |
| DE69428268T2 (en) | USE OF LOCALANE AESTHETIC FOR THE PRODUCTION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF BRONCHIAL AESTHMA | |
| AU645023B2 (en) | Compositions and method for treating painful, inflammatory or allergic disorders | |
| AU2007280625B2 (en) | Use of escin | |
| DE69825279T2 (en) | USE OF GLUCOSAMINE AND GLUCOSAMINE DERIVATIVES FOR THE FAST RELIEF OF JUCKREIZ OR LOCALIZED PAIN | |
| DE69725879T2 (en) | USE OF p-AMINOPHENOL DERIVATIVES FOR THE PRODUCTION OF PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | |
| US4369190A (en) | Analgesic composition and use thereof to ameliorate intractable pain | |
| US5376372A (en) | Analgesic and inflammation-reducing medicament | |
| EP0037488A2 (en) | Pharmaceutical composition for healing inflammatory and/or degenerative and/or atrophic mucous membranes | |
| CA2035443C (en) | Analgesic and inflammation-inhibiting medicament | |
| DE3545201A1 (en) | Synergistic combination of flupirtine and 4-acetamidophenol | |
| JP2002308764A (en) | Pharmaceutical composition for ophthalmic use | |
| EP0402208B1 (en) | Mixture of Vitamin A in physiological dosis and different active ingredients having therapeutic effect | |
| DE69904206T2 (en) | USE OF CETIRIZINE TO PREVENT ASTHMA ENTRY | |
| WO1993017674A1 (en) | Topical use of local anaesthetic agents for rheumatoid arthritis as well as a pharmaceutical preparation and a method for the treatment thereof | |
| EP1148883B1 (en) | Use of tricyclic antidepressants for treatment of headache | |
| ATE91890T1 (en) | MANUFACTURE OF A DRUG AGAINST ARTHRITIS AND RHEUMATISM. | |
| ATE275953T1 (en) | 2,3 DIARYL-1-BENZOPYRAMES FOR THE TREATMENT OF DERMATITIS | |
| DE3141970A1 (en) | MEDICINES FOR TREATING DISEASES GENERATED BY THE VIRUS OF THE HERPES GROUP | |
| DE4436127A1 (en) | Use of benzoic or pyridine:carboxylic acid or amide cpds. | |
| CA2352674A1 (en) | Natural therapeutic composition for the treatment of wounds and sores | |
| US4742076A (en) | Etodolac for lowering rheumatoid factor | |
| DE60210804T2 (en) | USE OF PROPIONYL L-CARNITINE OR ITS PHARMACOLOGICALLY ACCEPTABLE SALTS FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF LA PEYRONIE'S DISEASE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |